Four new studies were published in this month’s issue of the Journal of Diabetes Science and Technology touting patient outcomes linked to Glytec‘s eGlycemic diabetes management system, the company reported.
In both inpatient and outpatient settings, the use of eGMS for insulin therapy management was safer and more effective than traditional standards of care. The studies reported lower rates of hypoglycemia, quicker time to target glucose levels, sustained reductions in A1c levels and faster resolution of diabetic ketoacidosis associated with Glytec’s system.
One study compared computer-guided insulin infusion with standard regimens in 2,665 patients with diabetic ketoacidosis and found that patients using eGMS had 21% faster resolution of metabolic ketoacidosis and 93% reduction in severe hypoglycemia. The patients using eGMS spent 1.3 fewer days in the hospital compared to their counterparts, according to the study.
The second study assessed 54 critically-ill adult patients admitted to an intensive care unit, half of which were treated with eGMS and half of which were treated using paper-based protocols.
The study found a 99% reduction in time spent in severe hypoglycemia and a 94% decrease in hypoglycemia for patients using eGMS, as well as a 51% increase in the amount of time spent within target glucose range.
The third study was a quality improvement study involving a 580-bed academic medical center. The report found that the center had 2,434 fewer hypoglycemic events and 40,589 fewer hyperglycemic events in the first year after implementing eGMS. There was also a 47% decrease in the number of point-of-care blood glucose tests using eGMS.
Finally, the fourth study included 46 adult patients in an outpatient setting who were treated using Glytec’s Glucommander Outpatient module, which allows for insulin titration to be performed remotely between clinic visits.
The study showed a 3.1% absolute decrease in A1c over the course of 12 months and found that it took a median of seven days for patients to meet their prescribed glucose goal.
“It’s a great privilege to have worked with so many clinicians who are passionate about improving glycemic management in and out of the hospital, and are willing to do the hard work that research studies like these entail,” VP of quality initiatives, Raymie McFarland, said in prepared remarks.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.